Guardant Health
GH
#1740
Rank
A$16.76 B
Marketcap
A$127.80
Share price
1.76%
Change (1 day)
75.28%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Revenue for Guardant Health (GH)

Revenue in 2025 (TTM): A$1.49 Billion

According to Guardant Health 's latest financial reports the company's current revenue (TTM ) is A$1.42 Billion. an increase over the revenue in the year 2024 that were of A$1.18 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Guardant Health from 2018 to 2025

Annual revenue

Year Revenue Change
2025 A$1.46 B23.4%
2024 A$1.18 B43.54%
2023 A$0.82 B25.3%
2022 A$0.66 B28.17%
2021 A$0.51 B38.22%
2020 A$0.37 B21.79%
2019 A$0.30 B137.98%
2018 A$0.12 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Neogen
NEOG
A$1.27 B-10.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Natera
NTRA
A$3.34 B 134.83%๐Ÿ‡บ๐Ÿ‡ธ USA